Replies to post #12511 on Biotech Values

[randychub]

ymi - Cool - Don't take these questions to heart. Hopefully your hornets nest will bring new facts to light.

Taxotere does not have to be included in the label. If taxotere extends survival in this group of patients from 12.2 months to 15 months and the current tesmilifene trial extends life from 12.2 months to 30 months, which treatment will oncologist pick.

How much will it cost. Erbitux, Avastin, etc.. have proven to date, cost is no object. How long will this remain true? I would guess tesmilifene will be less expensive then avastin but that is just a guess.

First time I had seen this article which I found doing a a quick taxotere/tesmilifene search as a result of your post.

Randy

http://www.combichemlab.com/website/files/News/Press_Releases/2004/July-2004/Frost-Sullivan-1.htm

[io_io]

YMI

"The taxotere trial is not spa and there is no guarantee it will be included in the label."

Well I recall hearing Dr. Allan state the Tax trial would be under the umbrella of the current Tesm protocol....I posted this here before. I can't say he said that the SPA would be amended, but he used the word "umbrella".

As for a 6-hour infusion - is this a fact ? My knowledge on inufsions procedures is poor, but I think that this just needs a chair plus nurse in an infusion center/clinic, not necessarily the doctor's office.